SOURCE: Advanced Proteome Therapeutics Corporation

Advanced Proteome Therapeutics Corporation

April 13, 2015 09:15 ET

Advanced Proteome Therapeutics Corporation Announces Issuance of a New U.S. Patent for Modifying Proteins to Enhance Their Biological Activities

VANCOUVER, BC--(Marketwired - April 13, 2015) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) wishes to announce that the U.S. Patent and Trademark Office has issued U.S. Patent No. 8927485, which has been assigned to the Company. The invention is directed toward bundling two or more entities together to increase the biological activity of the individual entities. This type of approach in the industry has been key to developing new generations of anti-cancer drugs and diverse therapeutics. The modifications described can be used for the production and application of the bundled entities in the treatment of disorders such as rheumatoid arthritis and various autoimmune diseases, type-1 diabetes, and cancer. The patent, which expires in 2035, claims methods for the site-specific modification of peptides, polypeptides, and proteins, all of which represent species of viable therapeutics. The patent has been filed under the title of "Site-specific modification of proteins through chemical modification enabling protein conjugates, protein dimer formation, and stapled peptides" to emphasize the breadth of its utility.

Allen (Alexander) Krantz, Chief Executive Officer of APC, commented, "This recently issued patent is significant in that it forms part of an expanding patent estate that is designed to modify certain therapeutic proteins of interest to the Company. These proteins have shown demonstrable activity in tumor models of cancer, but require additional enhancements to elevate them to high level clinical interest. The Company's efforts over the past two years have been dedicated to achieving more effective retardation of tumor growth through protein modification, which we have accomplished with our collaborators in animal models of cancer."

"The Company continues to prosecute additional patent applications to protect its intellectual property in the form of methods and composition of matter directed towards cancer applications, which, if issued, would expand the scope of patent claims beyond 2035. In the coming weeks, the Company plans to file additional claims to create additional value for the Company, which, if granted, would cover a vast amount of intellectual property bearing on cancer applications and cover our progress in research and development to date and in the foreseeable future."

About APC

APC has been applying its Foundation Trinity™ Technology to proteins targeted for the treatment of cancers. Advanced targeted therapies are designed to attack primarily cancer cells and are expected to dominate the anti-cancer therapeutics' market in the near future. The Company's goals are not only to employ therapy targeted for tumor cells, but also to deliver combination therapy in a single, pure therapeutic agent, that can also, in turn, be combined with additional agents to enhance therapies.

To achieve this end, it has been the Company's intention to utilize a unique protein (and related systems), not only as a delivery vehicle to tumor cells, but also as a scaffold upon which to attach each anti-cancer entity to its own specific site on the protein surface -- both key to efficient manufacturing and product development. The protein vehicle has emerged as a potential immunotherapeutic as it is implicated in activating the immune system to attack and help clear tumor cells. Immunotherapy is perhaps the most powerful current approach to cancer, and one of great commercial interest to the pharmaceutical industry.

ON BEHALF OF THE BOARD
Alexander (Allen) Krantz
President and Chief Executive Officer

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:

    Advanced Proteome Therapeutics Corporation
    Alexander (Allen) Krantz
    President and Chief Executive Officer
    Tel: (617) 638-0340
    http://www.advancedproteome.com

    Scott Young
    Investor Relations
    Tel: (705) 888-2756